IGC Pharma, Inc.

Analysis for Ticker: IGC

IGC Pharma Inc is a clinical stage biotechnology company that uses artificial intelligence to develop treatments for Alzheimer's disease agitation and other neuropsychiatric disorders. The financial reality is a gruesome machine where the company burns nearly 4,8$ million in cash just to produce 1,2$ million in revenue from white-labeled hand sanitizers and hemp gummies. This is a business that functions like a child who spends 5$ on a lemonade stand just to make 1$ in sales and then expects the neighborhood to keep giving him money to cover the gap. By 03/2025, their cash was down to only 405.000$, and the only way they survive is by printing new shares of stock that dilute the ownership of everyone else until the original value is practically hollowed out. The machinery of extraction began with the company ballooning its outstanding shares from 53 million shares in 2023 to nearly 81 million shares by 03/2025 just to fund its operational deficits. While the internal cash evaporated, the insiders protected their own pockets. Chief executive officer Ram Mukunda drew a 360.000$ base salary and held 5,5 million unvested stock awards valued at 3,2$ million, while the company extracted 1,6$ million in total stock-based compensation for its leadership. In 04/2025, they sold 2,8 million shares to private investors at just 0,30$ each. By 07/2025, when the stock was trading at 0,34$, the company registered over 4,7 million shares for entities like the Brentwood Absolute Return Fund and individuals like Frank Zaccanelli to sell to the public. The company received 0$ from these sales but paid for all the legal and registration fees to help those private investors leave the building.